201 related articles for article (PubMed ID: 28993206)
21. Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease.
Scalia P; Maurancy J; Giordano A; Williams SJ
Crit Rev Eukaryot Gene Expr; 2021; 31(2):83-88. PubMed ID: 34347982
[TBL] [Abstract][Full Text] [Related]
22. EphrinB2-EphB4 Signaling in Neurooncological Disease.
Piffko A; Uhl C; Vajkoczy P; Czabanka M; Broggini T
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163601
[TBL] [Abstract][Full Text] [Related]
23. Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Liersch-Löhn B; Slavova N; Buhr HJ; Bennani-Baiti IM
Int J Cancer; 2016 Mar; 138(5):1220-31. PubMed ID: 26414866
[TBL] [Abstract][Full Text] [Related]
24. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Kumar SR; Singh J; Xia G; Krasnoperov V; Hassanieh L; Ley EJ; Scehnet J; Kumar NG; Hawes D; Press MF; Weaver FA; Gill PS
Am J Pathol; 2006 Jul; 169(1):279-93. PubMed ID: 16816380
[TBL] [Abstract][Full Text] [Related]
25. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
Kertesz N; Krasnoperov V; Reddy R; Leshanski L; Kumar SR; Zozulya S; Gill PS
Blood; 2006 Mar; 107(6):2330-8. PubMed ID: 16322467
[TBL] [Abstract][Full Text] [Related]
26. [Effects of bidirectional EphB4-EphrinB2 signaling on bone remodeling].
Fan WB; Zhao JN; Bao NR
Zhongguo Gu Shang; 2013 Aug; 26(8):705-8. PubMed ID: 24266083
[TBL] [Abstract][Full Text] [Related]
27. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Masood R; Kumar SR; Sinha UK; Crowe DL; Krasnoperov V; Reddy RK; Zozulya S; Singh J; Xia G; Broek D; Schönthal AH; Gill PS
Int J Cancer; 2006 Sep; 119(6):1236-48. PubMed ID: 16615113
[TBL] [Abstract][Full Text] [Related]
28. EphB4 forward-signaling regulates cardiac progenitor development in mouse ES cells.
Chen K; Bai H; Liu Y; Hoyle DL; Shen WF; Wu LQ; Wang ZZ
J Cell Biochem; 2015 Mar; 116(3):467-75. PubMed ID: 25359705
[TBL] [Abstract][Full Text] [Related]
29. EphB4 signaling is capable of mediating ephrinB2-induced inhibition of cell migration.
Sturz A; Bader B; Thierauch KH; Glienke J
Biochem Biophys Res Commun; 2004 Jan; 313(1):80-8. PubMed ID: 14672701
[TBL] [Abstract][Full Text] [Related]
30. Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Ferguson BD; Carol Tan YH; Kanteti RS; Liu R; Gayed MJ; Vokes EE; Ferguson MK; John Iafrate A; Gill PS; Salgia R
Sci Rep; 2015 Jun; 5():10641. PubMed ID: 26073592
[TBL] [Abstract][Full Text] [Related]
31. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2.
Héroult M; Schaffner F; Pfaff D; Prahst C; Kirmse R; Kutschera S; Riedel M; Ludwig T; Vajkoczy P; Graeser R; Augustin HG
Mol Cancer Res; 2010 Oct; 8(10):1297-309. PubMed ID: 21047731
[TBL] [Abstract][Full Text] [Related]
32. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
33. EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Xue C; Huang Z; Wang J; Dong Y; Zhou X
Can J Ophthalmol; 2009 Apr; 44(2):185-8. PubMed ID: 19491953
[TBL] [Abstract][Full Text] [Related]
34. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
35. Low concentrations of TNF-α promote osteogenic differentiation via activation of the ephrinB2-EphB4 signalling pathway.
Wang L; Zhang J; Wang C; Qi Y; Du M; Liu W; Yang C; Yang P
Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27726217
[TBL] [Abstract][Full Text] [Related]
36. Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Alam SM; Fujimoto J; Jahan I; Sato E; Tamaya T
Gynecol Oncol; 2009 Jul; 114(1):84-8. PubMed ID: 19356789
[TBL] [Abstract][Full Text] [Related]
37. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Zamora DO; Davies MH; Planck SR; Rosenbaum JT; Powers MR
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2175-82. PubMed ID: 15914639
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Bhatia S; Sharma J; Bukkapatnam S; Oweida A; Lennon S; Phan A; Milner D; Uyanga N; Jimeno A; Raben D; Somerset H; Heasley L; Karam SD
Clin Cancer Res; 2018 Sep; 24(18):4539-4550. PubMed ID: 29848571
[No Abstract] [Full Text] [Related]
39. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
40. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.
Yang NY; Pasquale EB; Owen LB; Ethell IM
J Biol Chem; 2006 Oct; 281(43):32574-86. PubMed ID: 16950769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
